PFE - Pfizer - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035

Vaccines, Medicines, Biosimilars, Injectables, Antivirals, Immunotherapies

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Web URL: https://www.pfizer.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for PFE - Pfizer  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for PFE - Pfizer  - Stock Price & Dividends

PFE Stock Overview

Market Cap in USD 169,828m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2012-08-13

PFE Stock Ratings

Growth 5y -4.44
Fundamental -26.2
Dividend 69.4
Rel. Performance vs Sector 0.60
Analysts 3.58/5
Fair Price Momentum 29.62 USD
Fair Price DCF 23.76 USD

PFE Dividends

Dividend Yield 12m 5.43%
Yield on Cost 5y 5.29%
Dividends CAGR 5y 3.75%
Payout Consistency 97.3%

PFE Growth Ratios

Growth 12m -9.66%
Growth Correlation 12m -43%
Growth Correlation 3m 35%
CAGR 5y -0.52%
CAGR/Mean DD 5y -0.03
Sharpe Ratio 12m -0.61
Alpha vs SP500 12m -24.85
Beta vs SP500 5y weekly 0.63
ValueRay RSI 98.17
Volatility GJR Garch 1y 24.02%
Price / SMA 50 9.11%
Price / SMA 200 11.81%
Current Volume 35657.1k
Average Volume 20d 32084.4k

External Links for PFE Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of PFE stocks?
As of July 27, 2024, the stock is trading at USD 30.77 with a total of 35,657,080 shares traded.
Over the past week, the price has changed by +4.12%, over one month by +13.80%, over three months by +24.70% and over the past year by -9.64%.
What are the forecast for PFE stock price target?
According to ValueRays Forecast Model, PFE Pfizer will be worth about 32.2 in July 2025. The stock is currently trading at 30.77. This means that the stock has a potential upside of +4.55%.
Issuer Forecast Upside
Wallstreet Target Price 31.6 2.83
Analysts Target Price 38.7 25.7
ValueRay Target Price 32.2 4.55

Discover Pfizer Inc: A Comprehensive Overview

History of Pfizer Inc.

Pfizer Inc., established in 1849 by Charles Pfizer and Charles F. Erhart, started as a fine chemicals business. The company's first product was an antiparasitic called santonin. Over the decades, Pfizer transformed into one of the world's premier biopharmaceutical companies. It played significant roles in medical advancements, including mass-producing penicillin during World War II and developing revolutionary drugs like Viagra and Lipitor.

Core Business

At its core, Pfizer is deeply devoted to discovering and producing healthcare solutions that improve life. Its primary focus is on developing medicines and vaccines for a plethora of medical fields, including immunology, oncology, cardiology, endocrinology, and neurology. The company prioritizes innovative research and is known for its robust pipeline of promising new therapies aimed at treating a wide range of diseases.

Side Businesses

Beside its main pharmaceutical products, Pfizer also engages in several side businesses. These include animal health products through its Zoetis division (spun off in 2013), over-the-counter (OTC) consumer health products, and various health-related digital services and platforms. These diversified interests help Pfizer maintain its financial stability and expand its healthcare impact beyond prescription medicines.

Current Market Status

As of 2023, Pfizer Inc. (NYSE: PFE) remains a leader in the pharmaceutical industry. The company has seen significant growth, largely due to the global demand for its COVID-19 vaccine, developed in partnership with BioNTech SE. This has not only boosted Pfizer's revenues but also its position in the market. However, like all companies in the sector, Pfizer faces challenges such as drug patent expirations, regulatory hurdles, and the ongoing need for innovative research and development. Despite these challenges, Pfizer's strong portfolio and pipeline, along with a proactive approach to global health crises, ensure it continues to play a vital role in the healthcare industry.